BAMCO Inc
ALNY icon

BAMCO Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

BAMCO Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,500
Closed -$1.39M – 329
2025
Q4 		$1.39M Hold
3,500
– – ﹤0.01% 292
2025
Q3 		$1.6M Buy
+3,500
New +$1.43M ﹤0.01% 289
2023
Q1 		– Sell
-11,650
Closed -$2.77M – 363
2022
Q4 		$2.77M Buy
11,650
+1,250
+12% +$267K 0.01% 302
2022
Q3 		$2.08M Buy
+10,400
New +$1.98M 0.01% 307
2022
Q2 		– Sell
-11,500
Closed -$1.88M – 370
2022
Q1 		$1.88M Buy
+11,500
New +$1.75M ﹤0.01% 339

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BAMCO Inc's ALNY Position: Q1 2026 in Review

BAMCO Inc sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,500 shares — an estimated $1.39M sold.

BAMCO Inc first reported a position in ALNY in Q1 2022 and held it in 5 quarters. The position peaked at $2.77M in Q4 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • BAMCO Inc reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • BAMCO Inc sold 3,500 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.39M.
  • BAMCO Inc first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • BAMCO Inc's Alnylam Pharmaceuticals position peaked at $2.77M in Q4 2022.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on BAMCO Inc's 13F filing for Q1 2026, filed 15 May 2026.